Applied Molecular Transport to Present at Jefferies Virtual London Healthcare Conference
Applied Molecular Transport (Nasdaq: AMTI) announced that CEO Tahir Mahmood, Ph.D., and CMO Bittoo Kanwar, M.D., will engage in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 17, 2020, at 12:00 p.m. ET / 5:00 p.m. GMT. A live webcast can be accessed through the company’s Events page, with an archived replay available for 30 days after the event.
AMT is focused on developing novel oral biologic therapies for autoimmune, inflammatory, and metabolic diseases, utilizing a unique technology platform for effective intestinal transport.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Applied Molecular Transport (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder of AMT, and Bittoo Kanwar, M.D., chief medical officer of AMT, will participate in a fireside chat during the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020 at 12:00 p.m. ET / 5:00 p.m. GMT.
A live webcast will be accessible via the Events page of the Applied Molecular Transport website at https://ir.appliedmt.com/news-events/events. An archived replay will be available for 30 days following the event.
About Applied Molecular Transport Inc.
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. AMT’s proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of diverse therapeutic modalities across the intestinal epithelium (IE) barrier. Active transport is an efficient mechanism that uses the cell’s own machinery to transport materials across the IE barrier. AMT believes that its ability to exploit this mechanism is a key differentiator of its approach. AMT is developing additional oral biologic product candidates in patient-friendly tablet and capsule forms that are designed to either target local gastrointestinal tissue or enter systemic circulation to precisely address the relevant biology of a disease.
AMT’s headquarters, internal GMP manufacturing and lab facilities are located in South San Francisco, CA. For additional information on AMT, please visit www.appliedmt.com.
Investor Relations Contact:
Andrew Chang
Head, Investor Relations & Corporate Communications
achang@appliedmt.com
Media Contacts:
Alexandra Santos
Wheelhouse Life Science Advisors
asantos@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
FAQ
What is the date of the fireside chat featuring AMTI's executives?
Who will participate in the AMTI fireside chat?
How can I access the AMTI fireside chat?
Will there be a replay of the AMTI fireside chat?
What are the main focuses of Applied Molecular Transport?
